A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

Figure 6 Change from baseline in number of days per week with no stool, hard, or very hard stools by treatment (ITT population). ^aP < 0.05 vs placebo; An improvement was defined as a decrease in the number of days with no stool, hard, or very hard stools (Bristol stool score of 1 or 2[19]) relative to baseline.